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Cardiac glycosides regulate endothelial tissue factor expression
in culture
Abstract
BACKGROUND: Tissue factor (TF) plays an important role in acute coronary syndromes and stent
thrombosis. This study investigates whether Na(+)/K(+)-ATPase regulates TF expression in human
endothelial cells. METHODS AND RESULTS: Ouabain inhibited tumor necrosis factor
(TNF)-alpha-induced endothelial TF protein expression; maximal inhibition occurred at 10(-5) mol/L,
reached more than 70%, and was observed throughout the 5 hours stimulation period. The decrease in
protein expression was paralleled by a reduced TF surface activity. Similarly, lowering of extracellular
potassium concentration inhibited TNF-alpha-induced TF protein expression. In contrast, ouabain did
not affect TNF-alpha-induced expression of full-length TF mRNA for up to 5 hours of stimulation;
instead, expression of alternatively-spliced TF mRNA was upregulated after 3 and 5 hours of
stimulation. Ouabain did not affect TNF-alpha-induced activation of the MAP kinases p38, extracellular
signal-regulated kinase (ERK), and c-Jun terminal NH(2) kinase; activation of Akt and p70S6 kinase
remained unaltered as well. Similar to the MAP kinases, ouabain did not affect TNF-alpha-induced
degradation of IkappaB-alpha. Ouabain had no effect on TF protein degradation. CONCLUSIONS:
Na(+)/K(+)-ATPase is required for protein translation of endothelial TF in culture. This observation
provides novel insights into posttranscriptional regulation of TF expression.
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Cardiac Glycosides Regulate Endothelial Tissue Factor
Expression in Culture
Barbara E. Sta¨hli, Alexander Breitenstein, Alexander Akhmedov, Giovanni G. Camici,
Kushiar Shojaati, Nikolay Bogdanov, Jan Steffel, Daniel Ringli, Thomas F. Lu¨scher, Felix C. Tanner
Background—Tissue factor (TF) plays an important role in acute coronary syndromes and stent thrombosis. This study
investigates whether Na/K-ATPase regulates TF expression in human endothelial cells.
Methods and Results—Ouabain inhibited tumor necrosis factor (TNF)-–induced endothelial TF protein expression;
maximal inhibition occurred at 105 mol/L, reached more than 70%, and was observed throughout the 5 hours
stimulation period. The decrease in protein expression was paralleled by a reduced TF surface activity. Similarly,
lowering of extracellular potassium concentration inhibited TNF-–induced TF protein expression. In contrast, ouabain
did not affect TNF-–induced expression of full-length TF mRNA for up to 5 hours of stimulation; instead, expression
of alternatively-spliced TF mRNA was upregulated after 3 and 5 hours of stimulation. Ouabain did not affect
TNF-–induced activation of the MAP kinases p38, extracellular signal-regulated kinase (ERK), and c-Jun terminal
NH2 kinase; activation of Akt and p70S6 kinase remained unaltered as well. Similar to the MAP kinases, ouabain did
not affect TNF-–induced degradation of IB-. Ouabain had no effect on TF protein degradation.
Conclusions—Na/K-ATPase is required for protein translation of endothelial TF in culture. This observation provides
novel insights into posttranscriptional regulation of TF expression. (Arterioscler Thromb Vasc Biol.
2007;27:2769-2776.)
Key Words: Ouabain  translation  thrombosis
Tissue factor (TF) is the main initiator of coagulation andthereby involved in the pathogenesis of acute coronary
syndromes.1 TF antigen and activity are indeed enhanced in
plaques from patients with unstable angina and myocardial
infarction as compared with those from patients with stable
angina.2 Moreover, increased TF plasma levels have been
detected in unstable angina and acute myocardial infarc-
tion.3,4 Given its role in initiating thrombus formation, it is
conceivable that TF may also be involved in the pathogenesis
of stent thrombosis, which remains a major concern owing to
its high morbidity and mortality.1,5,6 Indeed, drugs released
from drug-eluting stents such as rapamycin and paclitaxel
enhance endothelial TF expression and may thereby promote
thrombus formation after drug-eluting stent deployment.7,8
Na/K-ATPase is an ubiquitous transmembrane protein
regulating the active transport of sodium and potassium ions
across the cell membrane.9 As such, Na/K-ATPase is
important for cellular homeostasis. It is not known, however,
whether Na/K-ATPase influences TF expression and
thereby possibly thrombus formation. Cardiac glycosides
such as ouabain and digoxin inhibit Na/K-ATPase activity
in a very specific manner.10,11 As these drugs impair vascular
smooth muscle cell (VSMC) proliferation at higher concen-
trations,12 a concomitant negative effect on endothelial TF
expression would render them interesting candidate drugs for
application on drug-eluting stents. This study was therefore
designed to examine the effect of cardiac glycosides on
endothelial TF expression.
Materials and Methods
Cell Culture
Human aortic endothelial cells (HAECs) were obtained from Clo-
netics and cultured as described.13,14 Cells were grown to confluence
in 3-cm culture dishes, rendered quiescent for 24 hours in medium
containing 0.5% FCS, and stimulated with 5 ng/mL TNF alpha
(TNF-; R&D Systems). Ouabain, digoxin, carbenoxolone, glycyr-
rhizic acid, and cycloheximide (all from Sigma) were added to the
dishes 30 minutes before stimulation. In some experiments, the
medium was replaced 30 minutes before stimulation with Dulbecco’s
Modified Eagle Medium (DMEM) containing reduced potassium
concentrations and sodium concentrations adjusted to maintain
osmolarity. Cytotoxicity was assessed by a colorimetric assay for
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detection of lactate dehydrogenase (LDH) according to the manu-
facturer’s recommendations (Roche).
Western Blot Analysis
Western blot analysis was performed as described.15 Cells were
lysed in 50 mmol/L TRIS buffer, 25 g protein were loaded per lane,
and 10% SDS-PAGE was performed. Proteins were transferred to
polyvinylidene fluoride (PVDF) membranes (Millipore) by semidry
transfer. An antibody against human TF (American Diagnostica) was
used at 1:2000 dilution; antibodies against vascular cell adhesion
molecule (VCAM)-1 (R&D Systems) and heme oxygenase-1 (HO-1;
Stressgen) were used at 1:1000 and 1:5000 dilution, respectively.
An antibody against -tubulin (aT, 1:20000, Sigma) was applied as
loading control. Antibodies against phosphorylated p38 MAP kinase
(p38), phosphorylated p44/42 MAP kinase (ERK), and phosphory-
lated c-jun terminal NH2 kinase (JNK) (all from Cell Signaling) were
used at 1:1000, 1:5000, and 1:1000 dilution, respectively.
Antibodies against total p38, total ERK, and total JNK (all from
Cell Signaling) were used at 1:2000, 1:5000, and 1:1000
dilution, respectively. Antibodies against phosphorylated Akt
(Akt), phosphorylated p70S6 kinase (p70S6K), total Akt, and
total p70S6K (all from Cell Signaling) were applied at 1:1000,
1:2000, 1:1000, and 1:2000 dilution, respectively. Antibody
against IB- (from SantaCruz) was used at 1:2500 dilution.
Proteins were detected with a horseradish peroxidase linked
secondary antibody (Amersham).
Real-Time PCR
Total RNA was extracted from HAECs with 1 mL TRIzol Reagent
(Invitrogen) according to the manufacturer’s recommendations.13
Conversion of total cellular RNA to cDNA was carried out with
Moloney murine leukemia virus reverse transcriptase and random
hexamer primers (Amersham Bioscience) in a final volume of 33 L
using 4 g of RNA. The total cDNA pool obtained served as a
template for subsequent PCR amplification with primers specific for
full-length TF (sense primer: 5-TCCCCAGAGTTCACACCT-
TACC–3; bases 508 to 529 of F3 cDNA; NCBI no. NM 001993;
antisense primer: 5– CCTTTCTCCTGGCCCATACAC–3; bases
843 to 863 of F3 cDNA; NCBI no. NM 001993), or primers not
discriminating full-length and alternatively-spliced TF (sense
primer: 5-TCCCCAGAGTTCACACCTTACC–3; bases 508 to
529 of F3 cDNA; NCBI no. NM 001993; antisense primer: 5–
TGACCACAAATACCACAGCTCC–3; bases 892 to 913 of F3
cDNA; NCBI no. NM 001993).16 Real-time PCR amplification was
performed in a MX3000P PCR cycler (Stratagene) using the SYBR
Green JumpStart kit (Sigma) in 25 L final reaction volume
containing 2 L cDNA, 10 pmol of each primer, 0.25 L of internal
reference dye, and 12.5 L of JumpStart Taq ReadyMix (buffer,
dNTP, stabilizers, SYBR Green, Taq polymerase, and JumpStart Taq
antibody).16 The following cycling parameters were used: 95° for 10
minutes for 1 cycle, 95° for 30 seconds, 60° for 1 minute, 72° for 1
minute, for a total of 40 cycles. A melting curve analysis was
performed after amplification to verify the accuracy of the amplicon.
L28 primers served as loading control. Products were separated by
electrophoresis on a 1.5% agarose gel and visualized with ethidium
bromide. The identity of alternatively spliced TF PCR products was
confirmed by extraction from the agarose gel and sequencing
(Microsynth AG).
TF Surface Activity
TF surface activity was analyzed with a colorimetric assay (Ameri-
can Diagnostica) according to the manufacturer’s recommendations
with some modifications as described.17 Cells were grown to
confluence in 12-well plates. After stimulation with TNF-, cells
were washed twice with phosphate-buffered saline and incubated
with human FVIIa and FX at 37°, allowing for the formation of the
TF/FVIIa complex at the cell surface. This complex converted
human FX to FXa, which was measured by its ability to cleave a
chromogenic substrate. A standard curve was established with
lipidated human TF to assure that the results were in the linear range
of detection (data not shown).
ELISA
Expression of tissue-type plasminogen activator-1 (tPA) was ana-
lyzed with an ELISA assay (American Diagnostica) according to the
manufacturer’s recommendations. Cells were grown to confluence in
6-well plates and stimulated with TNF- with or without ouabain
pretreament (105 mol/L). 50 L of the media was used for ELISA.
To detect tPA in a linear range of detection, a standard curve was
established with provided tPA standards (data not shown).
Na/K-ATPase Activity
Unidirectional K-influx into HAECs was measured using 86Rb as a
radioactive tracer. HAECs were pretreated with ouabain at 106 to
104 mol/L for 15 minutes before addition of 86Rb. To estimate
unidirectional K-uptake, 86Rb accumulation in cells was moni-
tored in control and in ouabain-treated cells. Radioactivity of cell
lysates as well as that of the aliquots of incubation medium was
measured using Packard Tri-Carb 1600 TR liquid scintillation
counter (Packard, Meriden, CT). Unidirectional K-influx was
calculated from the slope in the linear part of the 86Rb accumu-
lation curve plotted against incubation time and normalized to
protein content in cell lysates.
Statistical Analysis
Data are given as meanSEM. Unpaired Student t test was per-
formed for statistical analysis. A probability value 0.05 denoted a
significant difference.
Results
Ouabain Inhibits TF Protein Expression and
Surface Activity
HAECs were stimulated with 5 ng/mL TNF- for 5 hours in
the presence or absence of ouabain (108 to 105 mol/L).
TNF- induced a 14-fold increase in TF protein expression as
compared with baseline (n10; P0.0001; Figure 1A and
1B). Ouabain inhibited TNF-–induced TF expression in a
concentration-dependent manner (n5; P0.001; Figure
1A); a maximal effect was observed at a concentration of 105
mol/L and reached more than 70%. Similar to ouabain,
digoxin decreased TNF-–induced TF expression in a
concentration-dependent manner (n5; P0.05; Figure 1D).
Ouabain blunted TNF-–induced TF expression already after
1 hour of stimulation, and this effect was maintained through-
out the stimulation period (n4; P0.05; Figure 1B). Con-
sistent with these observations, ouabain impaired TNF-–
induced TF surface activity by 44% (n5; P0.0001; Figure
1C). Neither ouabain nor digoxin affected basal TF expres-
sion (n5; PNS; Figure 1A and 1D).
Similar to its effect on TF expression, ouabain inhibited
TNF-–induced VCAM-1 protein expression; a 97% de-
crease was observed at 105 mol/L (n5; P0.0001; Figure
1E). In contrast, expression of HO-1 and aT was not affected
(n4 for HO-1, and n5 for aT, respectively; PNS; Figure
1E). Moreover, expression of tPA was not affected measured
by ELISA (n5; PNS; Figure 1F).
Ouabain has been described to interfere with the func-
tion of gap junctions.18,19 To investigate whether such an
action may be involved in its effect on TF expression, cells
were treated with carbenoxolon, a well-known gap junc-
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tion inhibitor, or with glycyrrhizic acid, a carbenoxolone
analogue inactive at the gap junction level,20,21 before
stimulation with TNF-. Neither carbenoxolon (109 to
106 mol/L) nor glycyrrhizic acid (109 to 106 mol/L)
affected TNF- induced TF expression (n8; PNS; data
not shown).
Ouabain, digoxin, carbenoxolon, and glycyrrhizic acid did
not affect LDH release at all the concentrations used (n5;
PNS; data not shown). Ouabain and digoxin slightly altered
endothelial cell morphology during incubation; the cells
appeared rounded, but remained attached to the dishes. The
effect on TF expression preceded these morphological
changes, which became only evident after more than 2 hours
(n5; data not shown).
Lowering Extracellular Potassium Concentrations
Decreases TF Protein Expression
Extracellular potassium concentration was lowered to impair
Na/K-ATPase activity.22 Decreasing the extracellular po-
tassium concentration inhibited TNF- induced TF expres-
sion in a concentration-dependent manner; a maximal effect
was observed in potassium-free medium, where TNF-–
induced TF expression was reduced by 77% (n4;
P0.0001; Figure 2A).
Ouabain Inhibits Na/K-ATPase Activity
Unidirectional K-influx into HAECs was measured using
86Rb as a radioactive tracer. Active Na/K-ATPase-mediated
K-influx comprised 86% of total K-influx into HAECs.
Ouabain completely inhibited Na/K-ATPase activity at a
concentration of 104 mol/L, whereas it decreased Na/K-
ATPase activity by 43% and 61% at 106 and 105 mol/L,
respectively (n5; P0.05; Figure 2B).
Ouabain Does Not Affect Expression of
Full-Length TF mRNA, but Upregulates
Alternatively-Spliced TF mRNA
Real-time PCR revealed that TNF- (5 ng/mL) induced expres-
sion of TF mRNA with a maximal effect occurring after 2 hours.
Induction of full-length TF mRNA was not affected by ouabain
(105 mol/L) (n5; PNS for each time point; Figure 3A). In
contrast, when TF mRNA expression was assessed with primers
not discriminating full-length and alternatively-spliced TF, treat-
ment with ouabain (105 mol/L) did not affect TF mRNA
expression for up to 2 hours, whereas expression was enhanced
by 2.0-fold after 3 hours (n5; P0.05; Figure 3B), and
3.3-fold after 5 hours (n5; P0.01; Figure 3B). Agarose gel
electrophoresis of the amplification products revealed a band at
384 bp, present at all time points examined and corresponding to
full-length TF, as well as a second band at 224 bp appearing only
after 3 and 5 hours of stimulation (Figure 3B); the PCR product
corresponding to this band was sequenced and identified as
alternatively-spliced TF. Hence, the ouabain-induced increase in
total TF mRNA expression at 3 and 5 hours occurred because of
upregulation of alternatively-spliced TF mRNA.
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Figure 1. Ouabain inhibits TF protein expression and surface activity. Ouabain inhibits TNF-–induced TF protein expression (A and B)
and surface activity (C). D, Digoxin inhibits TNF-–induced TF protein expression. E, Ouabain inhibits VCAM-1, but not HO-1 and aT,
protein expression. F, Ouabain does not affect tPA expression.
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Ouabain Does Not Affect Activation of
MAP Kinases
TNF- induced a transient phosphorylation of the MAP
kinases p38, ERK, and JNK, with maximal activation
occurring after 15 minutes of stimulation.23,24 The activa-
tion pattern of these MAP kinases was not affected by
ouabain (105 mol/L) at all time points examined (n4;
PNS for each time point; Figure 4A). Similarly, activa-
tion of Akt and p70S6K remained unaffected by ouabain
(n4; PNS for each time point; Figure 4B). Neither
TNF- nor ouabain altered total expression of MAP
kinases, Akt, or p70S6K.
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Figure 2. Lowering extracellular potassium con-
centration decreases TNF-–induced TF protein
expression. A, Lowering extracellular potassium
concentration decreases TNF-–induced TF
protein. B, Ouabain inhibits Na/K-ATPase
activity assessed by 86Rb-influx.
A
TNF-α
(hours)
Ouabain
(10-5 mol/L)
0     0    ½ ½ 1    1     2    2    3    3     5    5
+         +       +        +       +      +- - - - - -
TNF-α
(hours)
Ouabain
(10-5 mol/L)
0       ½ 1           2            3          5
+          +           +    +            +      +       
*
*
TNF-α  
(hours)
Ouabain
(10-5 mol/L)
0    0    ½ ½ 1    1     2    2    3    3     5    5
*
*
TNF-α
(hours)
Ouabain
(10-5 mol/L)
B
asTF
flTFflTF
+         +       +        +       +      +- - - - - -
0       ½ 1           2            3           5
+          +          +    +             +      +       
0
25
50
75
100
125
TF
/L
28
 
m
R
NA
ex
pr
es
si
o
n
 (%
)
0
25
50
75
100
125
TF
/L
28
 m
RN
A
ex
pr
es
si
o
n
 (%
)
-1
0
1
2
3
∆∆∆∆ ∆∆∆
∆
Ct
 
(T
F/
L2
8)
-1
0
1
2
3
∆∆∆∆ ∆∆∆
∆
Ct
 
(T
F/
L2
8)
Figure 3. Ouabain does not affect expression of full-length TF mRNA, but enhances alternatively-spliced TF mRNA. A, Ouabain does
not affect TNF-–induced full-length TF mRNA expression. B, Ouabain enhances TNF-–induced total TF mRNA expression at 3 and 5
hours.
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Figure 4. Ouabain does not affect p38, ERK, JNK, Akt, p70S6K, and NFB activation. TNF-–induced phosphorylation of p38,
ERK, JNK (A) as Akt and p70S6K (B) is not affected by ouabain. C, TNF-–induced degradation of IB- is not affected by
ouabain.
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Degradation of IB- was not altered by ouabain as
compared with control (n5; PNS for each time point;
Figure 4C).
Ouabain Does Not Affect TF Protein Degradation
HAECs were first pretreated with cycloheximide, an inhibitor
of protein translation, to block de novo protein synthesis
before stimulation with TNF- (5 ng/mL) for 3 hours.25
Cycloheximide (5 g/mL) abolished TNF- induced TF
protein expression (n3; P0.0001; data not shown) without
exerting any toxicity as determined by LDH release (n7;
PNS; data not shown). To assess whether ouabain promotes
TF protein degradation, TF protein expression was induced
by TNF- (5 ng/mL) for 3 hours and observed to remain
stable from 3 to 7 hours after TNF- stimulation (n5;
PNS for each time point versus TNF- stimulation at 3
hours; Figure 5A); then, ouabain (105 mol/L) was added in
the presence or absence of cycloheximide (5 g/mL) after 3
hours of TNF- stimulation. Ouabain alone did not affect the
level of TF protein expression throughout this time window
(n5, PNS for both TF protein expression and trend-line of
TNF- plus ouabain versus TNF- alone; Figure 5B). Cyclo-
heximide alone slightly reduced TF protein level from 3 to 7
hours after TNF- stimulation (n4; PNS for both TF
protein expression and trend-line of TNF- plus cyclohexi-
mide versus TNF- alone; Figure 5C). Ouabain did not affect
TF protein level in the presence of cycloheximide (n4;
PNS for both TF protein expression and trendline of TNF-
plus cycloheximide plus ouabain versus TNF- plus cyclo-
heximide; Figure 5D).
Discussion
This study demonstrates that cardiac glycosides such as
ouabain and digoxin inhibit TNF-–induced endothelial TF
protein expression and surface activity. Cardiac glycosides
specifically inhibit Na/K-ATPase activity by binding to its
 subunit.911 Ouabain indeed inhibited Na/K-ATPase
activity in HAECs as previously described in human arterial
and venous endothelial cells.11,26,27 Consistently, inhibition of
Na/K-ATPase, via reduced extracellular potassium concen-
trations, blunted TNF-–induced endothelial TF expression.
Ouabain has been described to inhibit gap junctions as
well18,28; however, an involvement of gap junctions in regu-
lating TF expression can be ruled out, because the gap
junction inhibitor carbenoxolone did not affect endothelial TF
protein expression. Hence, Na/K-ATPase activity is re-
quired for induction of endothelial TF protein expression in
culture.
Slight alterations in endothelial cell morphology after
cardiac glycoside treatment have been described previously
and been attributed to an effect of Na/K-ATPase on
adhesion molecules.22,29,30 The effect on TF expression pre-
ceded these morphological changes. A nonspecific action of
cardiac glycosides on cell viability can be excluded, as LDH
release was not enhanced; moreover, ouabain (107 mol/L) is
known to exert an antiapoptotic effect on human umbilical
vein endothelial cells,31 and to reduce VSMC death during up
to 30 hours of treatment (103 mol/L).32
TNF- induces TF expression via activation of the MAP
kinases p38, ERK, and JNK.15 TNF-–induced phosphoryla-
tion of these MAP kinases was not affected by ouabain.
Consistently, ouabain did not alter TNF-–induced expres-
sion of full-length TF mRNA, indicating that the effect of
ouabain on TF expression occurs at the posttranscriptional
level. Furthermore, ouabain did not enhance TF protein
degradation, implying that ouabain inhibits TF protein trans-
lation. Such an effect is consistent with a limited transfer of
amino acids from aminoacyl soluble ribonucleic acid to
polypeptide in the presence of low intracellular potassium
concentrations, which has been documented in different cell
lines.33–35 Hence, decreased intracellular potassium concen-
trations seem to determine translational regulation of endo-
thelial TF expression, probably at the level of polypeptide
formation. Posttranscriptional regulation of TF has not been
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Figure 5. Ouabain does not promote TF protein
degradation. A, TF protein expression is stable
from 3 to 7 hours after TNF- stimulation. B,
Ouabain does not affect TF protein expression.
C, Cycloheximide slightly reduces TF protein
expression. D, Ouabain does not affect TF pro-
tein expression in presence of cycloheximide.
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studied as well as transcriptional mechanisms; indeed, trans-
lational regulation of endothelial TF has only rarely been
observed before.7
In contrast to full-length TF mRNA, TNF-–induced
expression of total TF mRNA was enhanced after 3 and 5
hours of ouabain treatment. At these time points, a second
transcript appeared as a smaller-sized band on the agarose
gel. This band was sequenced and identified as alternatively-
spliced TF; thus, the ouabain induced increase in total TF
mRNA expression occurring after 3 and 5 hours was attrib-
utable to an increase in expression of alternatively-spliced TF
mRNA. Alternatively-spliced TF is expressed and released
from cytokine stimulated endothelial cells.16,36 The increase
in expression of alternatively-spliced TF mRNA in response
to ouabain, however, probably lacks any biological signifi-
cance, because ouabain concomitantly inhibits TF translation.
Despite this observation, an increase in alternatively-spliced
TF protein cannot be ruled out completely.
Endogenous ouabain has been isolated from human plas-
ma37,38; its biological role still remains controversial. In
humans, conditions such as physical exercise, essential hy-
pertension, and congestive heart failure are associated with
increased plasma concentrations of endogenous ouabain.39 In
human plasma, concentrations of 1010 mol/L have been
measured37,40; in view of such concentrations, endogenous
ouabain does not seem to regulate TF expression. The
reference range for serum concentrations of cardiac glyco-
sides such as digoxin is around 109 mol/L41,42; moreover, a
narrow therapeutic range limits systemic application of car-
diac glycosides at higher concentrations. Therefore, system-
ically applied glycosides do not seem to alter TF expression.
However, cardiac glycosides may be applied locally at much
higher concentrations, for example on drug-eluting stents.
Stent thrombosis remains a major concern after drug-eluting
stent deployment because of its high morbidity and mortali-
ty.5,6,43 TF may be induced by stenting and is a key factor in
the pathogenesis of stent thrombosis1; both antiproliferative
agents used on drug-eluting stents, paclitaxel and rapamycin,
do indeed enhance endothelial TF expression and thereby
promote thrombus formation.7,8 Similar to rapamycin and
paclitaxel, cardiac glycosides exerts antiproliferative effects
on human vascular smooth muscle cells,12 but in contrast
suppresses endothelial TF expression and thereby may reduce
late stent thrombosis. Thus, cardiac glycosides may represent
an interesting candidate drug to be applied on drug-eluting
stents.
In conclusion, this study indicates that Na/K-ATPase
regulates endothelial TF expression at the level of protein
translation. This observation provides novel insights into
posttranscriptional regulation of endothelial TF expression
and opens new clinical applications of cardiac glycosides.
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